- Global Locations -


Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705


Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531


Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates


Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Osteoarthritis Gene Therapy Market Outlook (2023 to 2033)

As per Future Market Insights, the osteoarthritis gene therapy market is forecasted to attain a valuation of US$ 7.5 billion by 2023-end. Global demand for osteoarthritis gene therapy is expected to soar at a CAGR of 7.9% to US$ 16 billion in 2033, supported by:

Data Points

Key Statistics

Expected Market Value in 2023

US$ 7.5 billion

Projected Market Value in 2033

US$ 16 billion

Growth Rate (2023 to 2033)

7.9% CAGR

The demand outlook is anticipated to develop steadfast during the forecast period.

The providers of this therapy are expected to go through a high demand phase that would offer them various opportunities for progress.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

The Future of Osteoarthritis Treatment: Unlocking the Prominent Drivers of the Gene Therapy Market's Success

  • Growing Awareness of Gene Therapy: The growing awareness of gene therapy and its potential benefits has been a significant driver of the osteoarthritis gene therapy market. Gene therapy is a relatively new and innovative field, and as more people become aware of its benefits, the demand for these treatments is expected to rise. The increased awareness of gene therapy has been driven by various factors, including increased media coverage, the growing body of research and clinical trials, and the increasing number of success stories shared by patients. This rising awareness has led to a greater willingness among patients to invest in treatments that can help improve their quality of life. It has also led to increased public and private funding for gene therapy research and development, which has helped advance the field and propel the growth of the osteoarthritis gene therapy market. The burgeoning awareness of gene therapy is expected to continue to play a critical role in driving the growth of the market in the coming years.
  • Increased Access to Healthcare: Increased access to healthcare is a prominent driver of the osteoarthritis gene therapy market. The availability of healthcare services and treatments has made it easier for people to access gene therapy treatments for osteoarthritis. This has been facilitated by the growth of the global economy and the increasing availability of funding for healthcare. As a result, more people are able to access gene therapy treatments, which have fueled the growth of the osteoarthritis gene therapy market. The rising availability of healthcare services in more countries has also led to an increase in the number of people who can access these treatments, which has further fueled the growth of the market. The increased access to healthcare has also encouraged more people to seek treatment for osteoarthritis, which has increased the demand for gene therapy treatments. The increased access to healthcare is expected to continue to play a critical role in driving the growth of the osteoarthritis gene therapy market in the coming years, providing new opportunities for the development of more advanced and effective treatments for osteoarthritis.

Unleashing the Power of Gene Therapy: Europe Emerges as a Hub for Osteoarthritis Market Growth

The development of the osteoarthritis gene therapy market in Europe is gaining momentum, with a focus on improving patient outcomes and addressing the unmet medical needs of those suffering from osteoarthritis. The increasing prevalence of the disease, coupled with advancements in gene editing and delivery technologies, is driving growth in the field.

Pharmaceutical companies are also investing heavily in the development of new treatments, with several clinical trials underway in the region. With the increasing awareness of the potential of gene therapy to address the underlying causes of osteoarthritis, the market is expected to continue to grow in Europe in the coming years, providing new and innovative treatments for patients.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Revolutionizing Osteoarthritis Treatment: Hospitals Seize the Gene Therapy Market's Thriving Opportunities

Hospitals are the most lucrative end-user of the osteoarthritis gene therapy market due to their role in delivering advanced medical treatments to patients. As the demand for effective treatments for osteoarthritis increases, hospitals are at the forefront of providing gene therapy as a potential solution. Numerous hospitals have a strong financial incentive to offer the latest treatments, as they can charge premium prices for these innovative therapies.

What are the major drivers of the Osteoarthritis Gene Therapy demand?

Osteoarthritis (OA) is one of the leading cause of disability in the western world. According to the Osteoarthritis Foundation International, the prevalence of OA is approximately 500 million people, globally.

The disease is characterized by being incurable, incurring immense treatment cost but responding very poorly to the treatment. The fact that OA is a debilitating disease and gene therapy provides a hope for treatment and pain reduction, there is a very high demand for this therapy, globally. This is one of the major driver for this market.

The presence of a large number of geriatric and target patients, as well as improved healthcare infrastructure in several countries in the Asia-Pacific region, is expected to open up market opportunities during the forecast period.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

CRISPR/Cas9 system: The latest technique in gene therapy

A novel approach to gene editing using the CRISPR / Ca9 system bypasses disease-causing mutations in a gene, providing treatment for single-gene-related genetic diseases such as cystic fibrosis, certain types of sickle cell anemia and other rare diseases.

The CRISPR / Ca9 system has created promising new therapies for genes that can target and correct disease-causing mutations in a gene. In this process, Cas9 - a bacterial protein - cuts DNA at a specific location where it can edit, trim the genetic sequence, or insert a new sequence before repairing the DNA.

USA and Canada: Osteoarthritis Gene Therapy demand outlook

The Osteoarthritis gene therapy market in the USA and Canada regions is expected to be slightly affected due to the COVID-19 pandemic. The demand is supposed to show slight growth due to the government investments in various R&D activities in cell based research.

Since the gene therapy can be personalized for every patient’s need, this is anticipated to drive the demand outlook in these regions.

Europe: Osteoarthritis Gene Therapy demand outlook

The European region dominated osteoarthritis gene therapy market during the year 2020. This can be attributed to various reasons that contribute to the demand of this therapy such as rising prevalence of osteoarthritis cases in the region, increased geriatric population due to increased access to advanced medical care and rising obesity rates in various countries of Europe.

Who are the key players in the Osteoarthritis Gene Therapy market?

The key players in osteoarthritis gene therapy demand outlook are

  • Flexion
  • GeneQuine
  • Novartis
  • Smith & Nephew
  • Genascence
  • Kolon TissueGene
  • Sanofi
  • Paraxel
  • Medipost co ltd
  • and Mundipharma.

On 19th November 2018, Mundipharma signed a multi-year agreement with Kolon Life Sciences, where they secured the exclusive rights for Invossa osteoarthritis therapy in Japan. This collaboration was intended to ensure that all the patients suffering from osteoarthritis in Japan had access to latest breakthrough treatments like Invossa.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments.

The report also maps the qualitative impact of various market factors on market segments and geographies.

Key Segments

By Site of Injection:

  • Synovium
  • Cartilage

By Vectors:

  • Non-viral
  • Retrovirus
  • Lentivirus
  • Adenovirus
  • Adeno-associated virus (AAV)
  • HSV

By End-User:

  • Hospitals and clinics
  • Orthopedic Centers
  • Assisted living Facilities
  • Nursing Homes
  • Ambulatory Surgical Centers
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • MEA



Porokeratosis Treatment Market

Published : January 2023


Transport Protein Assays Kits Market

Published : January 2023


Hyaluronic Acid Personal Care Products Market

Published : January 2023


Super Resolution Microscope Market

Published : January 2023

Explore Healthcare Insights

View Reports

Osteoarthritis Gene Therapy Market

Schedule a Call